LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies.

    Hassani, Danesh / Jeddi-Tehrani, Mahmood / Yousefi, Parisa / Mansouri-Fard, Samaneh / Mobini, Maryam / Ahmadi-Zare, Hengameh / Golsaz-Shirazi, Forough / Amiri, Mohammad Mehdi / Shokri, Fazel

    Cancer chemotherapy and pharmacology

    2022  Volume 89, Issue 3, Page(s) 347–361

    Abstract: Purpose: The therapeutic potential of targeting the human epidermal growth factor receptor-3 (ErbB3/HER3) has long been ignored due to impaired tyrosine kinase function and low expression level in tumor cells compared with EGFR and HER2. Although recent ...

    Abstract Purpose: The therapeutic potential of targeting the human epidermal growth factor receptor-3 (ErbB3/HER3) has long been ignored due to impaired tyrosine kinase function and low expression level in tumor cells compared with EGFR and HER2. Although recent investigations have explored the potential benefit of HER3 targeting and several anti-HER3 agents have been developed, there is still a critical need to design and produce more efficient therapeutics. This study was designed to develop tumor inhibitory monoclonal antibodies (MAbs) against different extracellular subdomains of HER3.
    Methods: Distinct extracellular subdomains of HER3 (D
    Results: Four anti-D
    Conclusion: Some of the anti-HER3 MAbs produced in this study displayed tumor inhibitory function and may be considered promising candidates for future HER3-targeted cancer therapy.
    MeSH term(s) Animals ; Antibodies, Monoclonal/pharmacology ; Cell Line, Tumor ; Humans ; Mice ; Receptor, ErbB-2/metabolism ; Receptor, ErbB-3 ; Trastuzumab/pharmacology
    Chemical Substances Antibodies, Monoclonal ; Receptor, ErbB-2 (EC 2.7.10.1) ; Receptor, ErbB-3 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
    Language English
    Publishing date 2022-01-26
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 6820-2
    ISSN 1432-0843 ; 0344-5704 ; 0943-9404
    ISSN (online) 1432-0843
    ISSN 0344-5704 ; 0943-9404
    DOI 10.1007/s00280-021-04390-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1420: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Does prior immunization with measles, mumps, and rubella vaccines contribute to the antibody response to COVID-19 antigens?

    Hassani, Danesh / Amiri, Mohammad Mehdi / Maghsood, Faezeh / Salimi, Vahid / Kardar, Gholam Ali / Barati, Omid / Hashemian, Seyed Mohammad Reza / Jeddi-Tehrani, Mahmood / Zarnani, Amir-Hassan / Shokri, Fazel

    Iranian journal of immunology : IJI

    2021  Volume 18, Issue 1, Page(s) 47–53

    Abstract: Background: Incidence and severity of SARS-CoV2 infection are significantly lower in children and teenagers proposing that certain vaccines, routinely administered to neonates and children may provide cross-protection against this emerging infection.: ...

    Abstract Background: Incidence and severity of SARS-CoV2 infection are significantly lower in children and teenagers proposing that certain vaccines, routinely administered to neonates and children may provide cross-protection against this emerging infection.
    Objective: To assess the cross-protection induced by prior measles, mumps and rubella (MMR) vaccinations against COVID-19.
    Methods: The antibody responses to MMR and tetanus vaccines were determined in 53 patients affected with SARS-CoV2 infection and 52 age-matched healthy subjects. Serum levels of antibodies specific for NP and RBD of SARS-CoV2 were also determined in both groups of subjects with ELISA.
    Results: Our results revealed significant differences in anti-NP (P<0.0001) and anti-RBD (P<0.0001) IgG levels between patients and healthy controls. While the levels of rubella- and mumps specific IgG were not different in the two groups of subjects, measles-specific IgG was significantly higher in patients (P<0.01). The serum titer of anti-tetanus antibody, however, was significantly lower in patients compared to healthy individuals (P<0.01).
    Conclusion: Our findings suggest that measles vaccination triggers those B cells cross-reactive with SARS-CoV2 antigens leading to the production of increased levels of measles-specific antibody.
    MeSH term(s) Age Factors ; Aged ; Antibodies, Viral/blood ; Antigens, Viral/immunology ; B-Lymphocytes/immunology ; B-Lymphocytes/virology ; Biomarkers/blood ; COVID-19/blood ; COVID-19/diagnosis ; COVID-19/immunology ; COVID-19/virology ; Case-Control Studies ; Cross Protection ; Cross Reactions ; Female ; Host-Pathogen Interactions ; Humans ; Immunization ; Immunoglobulin G/blood ; Male ; Measles-Mumps-Rubella Vaccine/immunology ; Measles-Mumps-Rubella Vaccine/therapeutic use ; Middle Aged ; SARS-CoV-2/immunology ; Tetanus Toxoid/immunology ; Tetanus Toxoid/therapeutic use
    Chemical Substances Antibodies, Viral ; Antigens, Viral ; Biomarkers ; Immunoglobulin G ; Measles-Mumps-Rubella Vaccine ; Tetanus Toxoid
    Language English
    Publishing date 2021-05-04
    Publishing country Iran
    Document type Journal Article
    ISSN 1735-367X
    ISSN (online) 1735-367X
    DOI 10.22034/iji.2021.87990.1843
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2.

    Hassani, Danesh / Amiri, Mohammad Mehdi / Mohammadi, Mehdi / Yousefi, Parisa / Judaki, Mohammad Ali / Mobini, Maryam / Golsaz-Shirazi, Forough / Jeddi-Tehrani, Mahmood / Shokri, Fazel

    Current research in translational medicine

    2021  Volume 69, Issue 2, Page(s) 103277

    Abstract: Background: The human epidermal growth factor receptor (HER/ErbB) family-targeted therapies result in a significant improvement in cancer immunotherapy. Monoclonal antibodies (MAb) against HER2 demonstrated a survival benefit for patients; however, drug ...

    Abstract Background: The human epidermal growth factor receptor (HER/ErbB) family-targeted therapies result in a significant improvement in cancer immunotherapy. Monoclonal antibodies (MAb) against HER2 demonstrated a survival benefit for patients; however, drug resistance unavoidably occurs due to the overexpression of HER3, which leads to treatment failure. Effective inhibition of HER3 besides HER2 is thought to be required to overcome resistance and enhance therapeutic efficacy.
    Objective: The present study describes the production and characterization of a novel MAb, designated 1G5D2, which acts as a natural bispecific antibody targeting extracellular domains (ECD) of both HER2 and HER3.
    Methods: In this study, 1G5D2 was produced by hybridoma technology against HER3-ECD, and its structural and functional characteristics were studied by various methodologies, including enzyme linked-immunosorbent assays, flow cytometry, immunoblotting, cell signaling, and cell proliferation assays.
    Results: 1G5D2 specifically binds to both HER2 (subdomain III + IV) and HER3 (subdomain I + II) expressed on tumor cells, and these receptors compete with each other for binding to this MAb. Competition flow cytometry experiments demonstrated that 1G5D2 does not compete with heregulin and recognizes an epitope out of HER3 ligand-binding site. Evaluation of 1G5D2 inhibitory effects in tumor cell lines co-expressing HER2 and HER3 showed that 1G5D2 synergizes with trastuzumab to inhibit both PI3K/AKT and MAPK/ERK pathways and potently downregulates the proliferation of these tumor cells more efficiently than each MAb alone.
    Conclusion: 1G5D2 is the first reported hybridoma antibody, which acts as a natural HER2/HER3 bispecific antibody. It might potentially be a suitable therapeutic candidate for HER2/HER3 overexpressing cancer types.
    MeSH term(s) Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Humans ; Hybridomas ; Phosphatidylinositol 3-Kinases ; Receptor, ErbB-2/genetics ; Receptor, ErbB-3/genetics
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Receptor, ErbB-2 (EC 2.7.10.1) ; Receptor, ErbB-3 (EC 2.7.10.1)
    Language English
    Publishing date 2021-02-24
    Publishing country France
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2452-3186
    ISSN (online) 2452-3186
    DOI 10.1016/j.retram.2021.103277
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients.

    Maghsood, Faezeh / Hassani, Danesh / Salimi, Vahid / Kardar, Gholam Ali / Khoshnoodi, Jalal / Ghaderi, Abbas / Raeeskarami, Seyyed Reza / Rostamian, Abdorrahman / Seyyedsalehi, Monireh Sadat / Ahmadi Fesharaki, Raoufeh / Jeddi-Tehrani, Mahmood / Zarnani, Amir-Hassan / Amiri, Mohammad Mehdi / Shokri, Fazel

    Viral immunology

    2021  Volume 34, Issue 10, Page(s) 708–713

    Abstract: The coronavirus infectious disease 2019 (COVID-19), which is initiated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed critical challenges to global health. Understanding the kinetic of SARS-CoV-2-specific IgM and IgG ... ...

    Abstract The coronavirus infectious disease 2019 (COVID-19), which is initiated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has imposed critical challenges to global health. Understanding the kinetic of SARS-CoV-2-specific IgM and IgG responses in different subsets of COVID-19 patients is crucial to get insight into the humoral immune response elicited against the virus. We investigated IgM and IgG responses against SARS-CoV-2 nucleocapsid (N) and receptor-binding domain (RBD) of spike protein in two groups of recovered and deceased COVID-19 patients. The levels of IgM and IgG specific to N and RBD proteins were detected by ELISA. N- and RBD-specific IgM was higher in deceased patients in comparison with recovered patients, while there was no significant difference in N- and RBD-specific IgG between the two groups. A significant correlation was observed between IgG and IgM titers against RBD and N, in both groups of patients. These results argue against impaired antibody response in deceased COVID-19 patients.
    MeSH term(s) Antibodies, Viral/analysis ; Antibodies, Viral/immunology ; Antibody Formation ; Antigens, Viral/immunology ; COVID-19/immunology ; COVID-19/mortality ; Female ; Humans ; Immunoglobulin G/analysis ; Immunoglobulin G/immunology ; Immunoglobulin M/analysis ; Immunoglobulin M/immunology ; Iran/epidemiology ; Male ; Middle Aged ; Nucleocapsid/chemistry ; Nucleocapsid/immunology ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/immunology
    Chemical Substances Antibodies, Viral ; Antigens, Viral ; Immunoglobulin G ; Immunoglobulin M ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
    Language English
    Publishing date 2021-09-17
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639075-4
    ISSN 1557-8976 ; 0882-8245
    ISSN (online) 1557-8976
    ISSN 0882-8245
    DOI 10.1089/vim.2021.0061
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2227: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top